UK NICE recommends use of Sequana's alfapump® for the treatment of refractory ascites caused by cirrhosis under special arrangements

Ghent, Belgium: 15 November 2018 - Sequana Medical NV, a commercial stage medical device company focused on the development of innovative treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders, announces today that the UK National Institute for Health and Care Excellence ("NICE") has published updated Interventional Procedures Guidance ("IPG") supporting the use of the alfapump® for the treatment of refractory ascites caused by cirrhosis. The updated IPG recommends use of the alfapump® under "special arrangements for clinical governance, consent, and audit or research" and replaces the previous guidance of February 2014 recommending the alfapump® for "research use only". The updated guidance is a result of the additional safety, efficacy and quality of life data published for the alfapump®.

More info on Sequana's website.

Next > iSTAR Medical’s MINIject maintains exceptional results in first-in-human trial one year post-surgery (STAR-I)

Previous > Sequana Medical announces the appointments of industry experts Pierre Chauvineau as Chairman and Wim Ottevaere as Non-Executive Director